Disease relevance of FPL-52694

• Inhibition of gastric acid secretion in conscious dog with fistula following intragastric administration of FPL 52694 [1].
• Although the precise mechanism of action of FPL-52694 remains unknown, oral FPL-52694 appears to be a promising agent for the treatment of peptic ulcers [2].

High impact information on FPL-52694

• It is concluded that FPL 52694 caused significant inhibition of acid secretion, and that the likely mechanism of action is by stabilisation of mast cells and inhibition of histamine release [3].
• Action of FPL 52694 on gastric acid secretion in the healthy human stomach [3].
• Inhibition of pentagastrin-stimulated acid output by intragastric administration of FPL 52694 was much greater than the maximum effect seen following intravenous infusion [4].
• Since IF was not reduced by the use of FPL 52694, it may be that this substance will not influence vitamin B12 metabolism [5].

Anatomical context of FPL-52694

• The present studies further suggest that the protection afforded by pretreatment with sodium cromoglycate or FPL-52694 may be unrelated to effects of these agents on the connective tissue mast cell population in the stomach [6].

Associations of FPL-52694 with other chemical compounds

• In a double blind crossover experiment in 16 healthy male volunteers, the effects of oral FPL 52694 and a matching placebo upon pentagastrin stimulated gastric acid secretion, gastric mucosal histamine content, and gastric mucosal mast cell count were compared [3].
• The mast cell stabilizing agent, FPL 52694, significantly inhibited the current responses to antigen, while cromoglycate and doxantrazole were ineffective [7].
• Inhibition of gastric acid secretion by sodium cromoglycate and FPL 52694 [8].
• The enhanced acid secretory response in the presence of L-NAME was also inhibited by cimetidine, FPL-52694 (a mast cell stabilizer) or sensory deafferentation [9].
• The lesions induced by 48/80 were prevented by FPL-52694 (a mast cell stabilizer) and methysergide but not tripelennamine [10].

Analytical, diagnostic and therapeutic context of FPL-52694

• The effect of FPL 52694 on overnight gastric secretion was tested in 15 dyspeptic individuals in a double-blind crossover study [5].
• Oral administration of methysergide and cyproheptadine (serotonin antagonists) and FPL-52694 (a mast cell stabilizer) potently inhibited the compound 48/80-induced lesions [11].

References